SLFN11 and telomere syndrome: This study evaluated SLFN11 as a prognostic and predictive biomarker for (neo-)adjuvant chemotherapy in STS.<h4>Materials and methods</h4>SLFN11 expression was assessed by immunohistochemistry in 242 patients with STS across different disease stages, using the H-score and percentage of positive tumor cells.